ATE375169T1 - Modifizierte peptide enthaltende pharmazeutische präparationen - Google Patents

Modifizierte peptide enthaltende pharmazeutische präparationen

Info

Publication number
ATE375169T1
ATE375169T1 AT01945007T AT01945007T ATE375169T1 AT E375169 T1 ATE375169 T1 AT E375169T1 AT 01945007 T AT01945007 T AT 01945007T AT 01945007 T AT01945007 T AT 01945007T AT E375169 T1 ATE375169 T1 AT E375169T1
Authority
AT
Austria
Prior art keywords
peptidel
amino acid
pharmaceutical preparations
preparations containing
containing modified
Prior art date
Application number
AT01945007T
Other languages
English (en)
Inventor
Frank Mattner
Wolfgang Zauner
Walter Schmidt
Michael Buschle
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Application granted granted Critical
Publication of ATE375169T1 publication Critical patent/ATE375169T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01945007T 2000-04-14 2001-04-17 Modifizierte peptide enthaltende pharmazeutische präparationen ATE375169T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT6572000 2000-04-14
PCT/EP2001/004313 WO2001078767A2 (en) 2000-04-14 2001-04-17 Pharmaceutical preparations comprising modified peptides

Publications (1)

Publication Number Publication Date
ATE375169T1 true ATE375169T1 (de) 2007-10-15

Family

ID=3678333

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01945007T ATE375169T1 (de) 2000-04-14 2001-04-17 Modifizierte peptide enthaltende pharmazeutische präparationen

Country Status (7)

Country Link
US (1) US20030095979A1 (de)
EP (1) EP1272215B1 (de)
JP (1) JP2003531128A (de)
AT (1) ATE375169T1 (de)
AU (1) AU2001267349A1 (de)
DE (1) DE60130877T2 (de)
WO (1) WO2001078767A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
CA2452909A1 (en) * 2001-12-07 2003-06-13 Intercell Ag Immunostimulatory oligodeoxynucleotides
CA2484941A1 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
EP1601770B1 (de) 2003-03-04 2009-09-02 Intercell AG Streptococcus pyogenes antigene
ES2562456T3 (es) 2003-03-24 2016-03-04 Valneva Austria Gmbh Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
EP1608756B1 (de) 2003-03-31 2009-11-18 Intercell AG Staphylococcus epidermidis antigene
EP2333114A1 (de) 2003-04-15 2011-06-15 Intercell AG S. pneumoniae Antigene
EP1620460A2 (de) 2003-05-07 2006-02-01 Intercell AG Streptococcus agalactiae-antigene i + ii
CN102304527A (zh) 2003-05-30 2012-01-04 英特塞尔股份公司 肠球菌抗原
CA2530062A1 (en) 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
CA2583026A1 (en) * 2004-10-29 2006-05-04 Intercell Ag Hcv vaccines for chronic hcv patients
EP1827471B1 (de) * 2004-11-09 2011-01-12 Celtek Bioscience, Llc. Zusammensetzung und verfahren zur erhöhung der apoptose in krebszellen
EP2319862A1 (de) 2006-07-07 2011-05-11 Intercell AG Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
WO2008031133A2 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
US8343510B2 (en) 2007-01-12 2013-01-01 Intercell Ag Protective proteins of S. agalactiae, combinations thereof and methods of using the same
EP2152731A2 (de) 2007-05-02 2010-02-17 Intercell AG Klebsiella-antigene
AU2008265218A1 (en) 2007-06-18 2008-12-24 Intercell Ag Chlamydia antigens
CN101977927A (zh) 2008-03-17 2011-02-16 英特塞尔股份公司 针对肺炎链球菌保护的肽以及与其有关的组合物、方法和用途
US20130243779A1 (en) 2009-02-05 2013-09-19 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (de) 2009-02-13 2012-01-18 Intercell AG Nicht typisierbare haemophilus influenza-antigene
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
EP2915543B1 (de) 2014-03-04 2018-05-09 Albert-Ludwigs-Universität Freiburg Aus Enterococcus abgeleitete Polypeptide und Verwendung davon zur Impfung und Erstellung von therapeutischen Antikörpern
EP3363459A1 (de) 2017-02-17 2018-08-22 Alexander Klimka Polypeptid-epitope von s. aureus und entsprechende monoklonale antikörper zur behandlung von infektionen und immundiagnose

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5824315A (en) * 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
AU5801896A (en) * 1995-05-23 1996-12-11 Scripps Research Institute, The Antigen-specific activation of unprimed cd8+ t cells
ATE227584T1 (de) * 1995-05-24 2002-11-15 Hawaii Biotech Group Untereinheitsimpfstoff gegen flavivirus infektion
AU724399B2 (en) * 1995-08-18 2000-09-21 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies

Also Published As

Publication number Publication date
WO2001078767A2 (en) 2001-10-25
EP1272215A2 (de) 2003-01-08
DE60130877D1 (de) 2007-11-22
WO2001078767A3 (en) 2002-02-28
DE60130877T2 (de) 2008-07-17
JP2003531128A (ja) 2003-10-21
EP1272215B1 (de) 2007-10-10
AU2001267349A1 (en) 2001-10-30
US20030095979A1 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
DE60130877D1 (de) Modifizierte peptide enthaltende pharmazeutische präparationen
AU764589B2 (en) Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
IL92853A0 (en) Human insulin analogues,their preparation and pharmaceutical compositions containing them
AP2000001905A0 (en) Peptide compositions and formulations and use of same.
AU5532490A (en) Novel tnf-inhibit proteins and their preparation
KR880009045A (ko) 혈액 응고 방지성 펩티드
BG102714A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
PL336295A1 (en) Modified tnfalpha molecule, dna encoding such molecule and vaccine comprising such tnfalpha molecule and such dna
NO20053027D0 (no) Gastrinpreparater og formuleringer, og fremgangsmater for anvendelse og fremstilling.
AU2003264514A1 (en) Wt1 substitution peptides
PH12012502372A1 (en) Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
IE57698B1 (en) Modified protease inhibitors,process for their preparation,and pharmaceutical compositions prepared therefrom
US11065304B2 (en) Peptide pharmaceuticals for insulin resistance
TR199802534T2 (xx) Leptin (OB Protein) fragmanlar�
AR006517A1 (es) Polipeptido que alcanza un total de alrededor de 30 aminoacidos; sustancia, peptidomimetico y composicion farmaceutica resultantes; usos del polipeptidoy proceso para la sintesis del polipeptido.
EP1319023B8 (de) Peptid aus hsp70 welches nk zellaktivität stimuliert und seine verwendung
Shinkai et al. Amino acid sequence of cytochrome c 3 from Desulfovibrio vulgaris, Miyazaki
NZ333606A (en) Isolated peptides derived from MAGE-2
HUP0105094A2 (hu) IGF-I- és IGF-II-gátló növekedési hormont leadó hormon antagonista analógjai és alkalmazásuk
ATE392428T1 (de) Arzneimittel enthaltend analgetische peptide
KR910007960A (ko) 항응고성 펩티드
ATE42308T1 (de) Pharmakologisch aktive peptide.
NO942360L (no) Vaksine og polypeptider som er nyttige for denne
CA2423004A1 (en) Peptide inhibitors of hiv entry
Corran et al. The tryptic peptides of rabbit muscle triose phosphate isomerase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272215

Country of ref document: EP

REN Ceased due to non-payment of the annual fee